EPS for Stellar Biotechnologies, Inc. (SBOT) Expected At $-0.14

December 12, 2017 - By Nellie Frank

 EPS for Stellar Biotechnologies, Inc. (SBOT) Expected At $ 0.14

Analysts expect Stellar Biotechnologies, Inc. (NASDAQ:SBOT) to report $-0.14 EPS on December, 13.They anticipate $0.01 EPS change or 7.69 % from last quarter’s $-0.13 EPS. After having $-0.12 EPS previously, Stellar Biotechnologies, Inc.’s analysts see 16.67 % EPS growth. The stock decreased 2.70% or $0.0289 during the last trading session, reaching $1.0411. About 131,989 shares traded or 136.82% up from the average. Stellar Biotechnologies, Inc. (NASDAQ:SBOT) has declined 60.19% since December 12, 2016 and is downtrending. It has underperformed by 76.89% the S&P500.

Stellar Biotechnologies, Inc., a biotechnology company, engages in the aquaculture, research and development, manufacture, and commercialization of keyhole limpet hemocyanin protein primarily in Europe, the United States, and Asia. The company has market cap of $10.95 million. It provides KLH, an immune-stimulating molecule used as an active pharmaceutical ingredient in various immunotherapies; and as an injectable product to assess immune response. It currently has negative earnings. The firm offers its KLH protein under the Stellar KLH brand.

More recent Stellar Biotechnologies, Inc. (NASDAQ:SBOT) news were published by: Prnewswire.com which released: “Stellar Biotechnologies Expands Operations Team” on June 07, 2017. Also Streetinsider.com published the news titled: “Stellar Biotechnologies (SBOT) to Sell ‘Immunogen & Vaccine Technology’ to …” on March 13, 2017. Prnewswire.com‘s news article titled: “Stellar Biotechnologies Reports Fiscal Year 2017 Financial Results” with publication date: December 01, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.